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INTRODUCTION  Intervertebral disc degeneration and associated spinal
disorders (i.e., degenerative spondylosis, spinal stenosis, disc herniation,
radiculopathy, myelopathy) are leading sources of patient morbidity and
increased health care costs.  Disc degeneration is characterized in part by
progressive decrease in proteoglycan content leading to dehydration of the
nucleus pulposus.  Although growth factors (such as TGF-ß1, IGF-1, OP-1,
and BMP-2) appear to have promising therapeutic properties such as
stimulating proteoglycan synthesis [1-4], repeated injection of growth factor
protein(s) to the disc for chronic types of disease such as disc degeneration is
currently impractical.  An alternative possibility is genetic modification of
disc cells through gene transfer such that the cells manufacture the desired
growth factors endogenously, on a continuous basis.  In previous studies, a
direct, in-vivo adenovirus-mediated gene transfer technique has successfully
delivered exogenous marker genes and therapeutic genes to rabbit lumbar
intervertebral discs [5,6].  Furthermore, the susceptibility and anabolic
response of human intervertebral disc cells to an adenovirus-mediated
approach has been demonstrated [7].  However, the optimal combination of
anabolic growth factor genes for matrix regeneration is unknown.
Accordingly, the objectives of this in-vitro study were (1) to attempt
combination or “cocktail” gene therapy to human disc cells cultured in
alginate beads, and (2) to determine which combination can produce the most
synergistic or additive effect on matrix synthesis.  
METHODS  All of the experimental protocols were approved by the human
subjects Institutional Review Board of the University of Pittsburgh.  Lumbar
and cervical intervertebral disc tissue of grade III degeneration (as classified
by preoperative MRI) was obtained from 7 patients during surgical disc
procedures.  Disc cells were isolated from the disc tissue by sequential
enzymatic digestion [8].  At full adherence of cells, individual cultures were
transduced singly with Ad/TGF-ß1, Ad/IGF-1, and Ad/BMP-2, with a
combination of two viral constructs (Ad/TGF-ß1 + Ad/IGF-1, Ad/IGF-1 +
Ad/BMP-2, and Ad/TGF-ß1 + Ad/BMP-2), and with a combination of three
viral constructs (Ad/TGF-ß1 + Ad/IGF-1 + Ad/BMP-2).  Additional cultures
treated with normal saline and Ad/luciferase served as controls.  Total viral
concentration applied to each culture was adjusted to 3.75x107 PFU, MOI =
75.  All cultures were incubated at 37°C for one hour with gentle agitation.
Newman-Tytel serumless medium (950 µl) was added to each well, and the
cells were further incubated at 37°C for 24 hours for stabilization of the cells.
The cultures were then trypsinized and incorporated into alginate beads [9].
The alginate beads were incubated for 48 hours.  Transgene expression (TGF-
ß1, IGF-1) was assessed by ELISA (R&D).  Newly synthesized proteoglycan
was assessed by 35S radioactive sulfate incorporation using chromatography
on Sephadex G-25 in PD-10 columns.  Scintillation count was normalized by
cell number at the end of the culture period.  One-way analysis of variance
with Fisher’s protected LSD post-hoc test was conducted to compare amounts
of newly synthesized proteoglycans.  Significance level was set p<0.05.
RESULTS  Cell viability remained high (90-95%) during the viral
transduction and alginate incorporation procedures.  TGF- ß1 and IGF-1
concentration increased markedly in conditioned medium, confirming
successful transgene expression.  In cultures transduced with a single
therapeutic gene, there were statistically significant increases in newly
synthesized proteoglycans (295% for Ad/TGF-ß1, 180% for Ad/IGF-1, and
190% for Ad/BMP-2) as compared with control cultures (p<0.05).  In cultures
transduced with a double combination of therapeutic genes, the increases in
newly synthesized proteoglycans as compared with control cultures were
398% for Ad/TGF-ß1 + Ad/IGF-1, 322% for Ad/IGF-1 + Ad/BMP-2, and
348% for Ad/TGF-ß1 + Ad/BMP-2 (p<0.05).  Cultures transduced with a
cocktail of three therapeutic genes (Ad/TGF-ß1 + Ad/IGF-1 + Ad/BMP-2)
demonstrated a 471% increase in newly synthesized proteoglycan as
compared with control cultures (p<0.05).
DISCUSSION  Efficient and reliable methods to deliver exogenous gene(s) to
the intervertebral disc have become available with recent developments in
molecular biology and vector technology.  The optimal combination of
exogenous genes for the management of degenerative disc disease, however,
is unknown.  While the cDNAs of anabolic growth factors as well as catabolic
cytokines and enzymes are available, most research efforts to date have
focused on enhancing the anabolic aspects of disc metabolism—hence the
emphasis has been on anabolic growth factors.  The current study has
investigated the effect of combination or “cocktail” gene therapy on disc
matrix synthesis by human intervertebral disc cells cultured in three-
dimensional alginate beads.  The current study has demonstrated robust
anabolic effects on matrix synthesis which seem to be additive and
synergistic, depending upon the combination of genes applied.  Extrapolation
of the current in-vitro results obtained with cultured human disc cells to in-
vivo clinical situations is, of course, premature, and requires further validation
of the combination gene therapy approach in animal models.  We are also
actively characterizing gene expression profiles as a function of the disc
degeneration process to better guide the optimal selection of genes for
therapeutic/prophylactic intradiscal gene therapy approaches.  In conclusion,
combination or “cocktail” gene therapy offers a promising method for
maximizing matrix regeneration for low dose viral mixtures.
FIGURE 1.  Newly synthesized proteoglycans (percent of control) produced
by human intervertebral disc cells transduced by different combinations of
therapeutic adenoviral vectors (Ad/TGF-ß1, Ad/IGF-1, Ad/BMP-2) and
cultured in three-dimensional alginate beads.  Error bars denote standard
deviation.  All experimental groups showed significant increase in
proteoglycan synthesis compared to saline and viral (Ad/luciferase) control
groups (p<0.05).
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